Brackett Erania
Known title: SVP, Chief Marketing OfficerCIK: 0001877055
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
Transaction History
| KN | ▲ Buy | Grant | 10,740 | $170K | 4/30/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 3,545 | $0 | 3/4/2024 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 279 | $9K | 3/1/2024 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 379 | $13K | 3/1/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 91 | $0 | 1/12/2024 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 2,435 | $72K | 11/16/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 128 | $0 | 10/13/2023 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 127 | $5K | 8/9/2023 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 120 | $5K | 8/9/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 112 | $0 | 7/14/2023 | View on chart |
| KN | ▲ Buy | Grant | 10,514 | $170K | 5/16/2023 | View on chart |
| KN | ▲ Buy | Grant | 10,109 | $163K | 5/16/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 790 | $0 | 5/4/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 111 | $0 | 4/14/2023 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 275 | $11K | 3/3/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 3,227 | $0 | 3/3/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 112 | $0 | 1/9/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 32,680 | $0 | 11/16/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 18 | $0 | 10/14/2022 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 125 | $5K | 8/9/2022 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 118 | $4K | 8/9/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 16 | $0 | 7/8/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 12 | $0 | 4/8/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 2,345 | $0 | 3/4/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 5 | $0 | 1/14/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 4 | $270 | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Knowles faces mixed signals with insider sale and analyst caution
Knowles is in focus this week as it prepares to attend the Midwest IDEAS Conference, with discussion building around what counts as a fair value for the stock. At the same time, several analyst pieces are highlighting concerns about the company's risk profile, with one naming Knowles among Russell 2000 names to avoid and another suggesting investors look at a different stock instead. Adding to the picture, company Director Shavers sold $260,000 worth of stock. The stock is trading near the middle of its 52-week range, with a trailing P/E well above peers and an average analyst price target of $43.75.
Knowles faces mixed signals with insider sale and analyst caution. Knowles is in focus this week as it prepares to attend the Midwest IDEAS Conference, with discussion building around what counts as a fair value for the stock. At the same time, several analyst pieces are highlighting concerns about the company's risk profile, with one naming Knowles among Russell 2000 names to avoid and another suggesting investors look at a different stock instead. Adding to the picture, company Director Shavers sold $260,000 worth of stock. The stock is trading near the middle of its 52-week range, with a trailing P/E well above peers and an average analyst price target of $43.75.